Effects of exercise on immune function in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates how both short-term and long-term exercise impacts the immune characteristics of patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. The study aims to assess the response of immune cells to acute exercise and a 12-week exercise training program, comparing these responses to age-matched controls. It also evaluates the effectiveness of exercise in reducing cancer-related side effects and improving quality of life and physical fitness. Additionally, the study will develop an AI system to optimize exercise training results for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* English speaking
* Between the ages of 18-80
* Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL/SLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study

Exclusion Criteria:

* Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease \[COPD\], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker
* Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate

Where it's running

• Mayo Clinic in Arizona
  Scottsdale, Arizona, United States Recruiting
• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Michael P. Gustafson, PhD — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirtobrutinib for Elderly CLL: See if this BTK inhibitor helps older adults

  This study tests whether pirtobrutinib can help people aged 75 and older with chronic lymphocytic leukemia that hasn’t been treated yet.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07685717

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• DZD8586 plus venetoclax for CLL/SLL

  This will try DZD8586 together with venetoclax in adults with newly diagnosed or treatment‑naïve CLL/SLL who need therapy.

  Recruiting at 14 sites Phase 2 Dizal Pharmaceuticals · Hefei, Anhui and 14 other locations · NCT07154264

• DZD8586 compared with doctor’s choice treatments for relapsed/refractory CLL/SLL

  This trial will test whether the oral drug DZD8586 works better than commonly chosen treatments for adults with relapsed or refractory CLL/SLL.

  Recruiting at 2 sites Phase 3 Dizal Pharmaceuticals · Nanjing, Jiangsu and 1 other locations · NCT07139873

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.